In this episode, Nir Barzilai, director of the Institute for Aging Research and expert in the genetics of longevity, discusses the evidence that metformin and rapamycin have anti-aging properties and how his TAME study aims to support this hypothesis in humans. Additionally, he describes the role of genetics in lifespan/healthspan and how it might affect important pathways such as IGF and insulin sensitivity.
We discuss:
Nir’s background and interest in aging and endocrinology [3:30];
History of metformin, and understanding the mechanism [11:15];
Attempting to define insulin resistance [21:15];
Metformin as a possible anti-aging drug [48:45];
The TAME trial: Targeting Aging with MEtformin [57:45];
Why Nir believes metformin can slow aging [1:16:30];
The genetic gift of centenarians [1:28:00];
IGF/GH and its impact on aging and chronic diseases [1:34:15];
Genetics/epigenetics of centenarians, gene sequencing, CETP-VV, Lp(a) [1:49:15];
Should you be taking HGH? [2:05:30];
NAD and NAD precursors (NR and NMN) [2:30:00];
Parting thoughts on metformin [2:36:15];
Possible blind spots in Nir and Peter’s thinking? [2:43:00]; and
Podden och tillhörande omslagsbild på den här sidan tillhör Peter Attia, MD. Innehållet i podden är skapat av Peter Attia, MD och inte av, eller tillsammans med, Poddtoppen.
